Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label Study Evaluating the Safety and Efficacy of Oral Soquelitinib in Adults With Moderate-to-Severe Hidradenitis Suppurativa

NCT07828860 is registered in ClinicalTrials.gov with Corvus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07828860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07828860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label Study Evaluating the Safety and Efficacy of Oral Soquelitinib in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Lead sponsor
Corvus Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 17, 2026
Completion date
December 31, 2027
Enrollment
25 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)